Scarica l'app Stockscreener
10.88
0.27%
-0.03
Dopo l'orario di chiusura:
10.88
Precedente Chiudi:
$10.91
Aprire:
$10.95
Volume 24 ore:
2.45M
Relative Volume:
1.25
Capitalizzazione di mercato:
$1.13B
Reddito:
-
Utile/perdita netta:
$-135.21M
Rapporto P/E:
-7.6025
EPS:
-1.4311
Flusso di cassa netto:
$-114.35M
1 W Prestazione:
+0.46%
1M Prestazione:
+45.07%
6M Prestazione:
+25.35%
1 anno Prestazione:
+2.16%
Intervallo 1D:
$10.29
$11.05
Intervallo di 1 settimana:
$10.29
$12.06
Portata 52W:
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
10.88 | 1.13B | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-11-20 | Iniziato | Evercore ISI | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth - AD HOC NEWS
Price to sales forward of Oric Pharmaceuticals, Inc. – DUS:4TZ - TradingView
ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan
[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals stock extends rally with bullish signals after 22 percent weekly surge - Traders Union
ORIC awards new hires 44,400 stock options and 7,200 RSUs - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation - MSN
Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Price to earnings forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Behavioral Patterns of ORIC and Institutional Flows - Stock Traders Daily
ORIC gains as Stifel resumes at buy on upcoming Pfizer readout - MSN
Oric Pharmaceuticals stock trades up as price holds above key supports despite mixed momentum - Traders Union
Oric Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ORIC) - TradingView
ORIC Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Oric Shareholders Approve Equity Plan, Governance Measures - TipRanks
ORIC Pharmaceuticals (ORIC) shareholders back updated equity plan and annual say-on-pay - Stock Titan
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Oric Pharmaceuticals stock drops 1.62% as Oric Pharmaceuticals marks Juneteenth with diversity message - Traders Union
Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oric Pharmaceuticals Inc (ORIC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oric Pharmaceuticals Inc (ORIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oric Pharmaceuticals Inc (ORIC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oric Pharmaceuticals Inc (ORIC) Institutional Confidence - TradingKey
Oric Pharmaceuticals Inc (ORIC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oric Pharmaceuticals Inc (ORIC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
(ORIC) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate - Sahm
ORIC Pharmaceuticals (ORIC) Gains on Buy Rating from Stifel Amid Positive Trial Outlook - GuruFocus
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE) - The Globe and Mail
Stifel initiates Oric Pharmaceuticals stock with buy rating By Investing.com - Investing.com Australia
Buy Rating and $14 Target Set for Oric Pharmaceuticals (ORIC) - GuruFocus
Stifel initiates Oric Pharmaceuticals stock with buy rating - Investing.com
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
ORIC: Phase III prostate cancer trial set to start, with strong safety and efficacy data and robust cash runway - TradingView
Oric Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
ORIC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Oric Pharmaceuticals stock edges up 1.60% as company executives join Goldman Sachs healthcare event, oricpharma - Traders Union
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com South Africa
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):